4590 results about "Intestino-intestinal" patented technology

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and/or to develop and monitor the outcome of therapeutic treatments. An exemplary disease/condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.

The invention relates to a lactobacillus microcapsule, a method for preparing the same, and the use of the same. The lactobacillus microcapsule consists of an outer layer of wall material, a freeze dried protective agent and lactobacilli. The invention also provides the method for preparing the lactobacillus microcapsule and the use of the lactobacillus microcapsule as a feed additive. The lactobacillus microcapsule can effectively protect the lactobacilli in a core material, prolong the survival time of the lactobacilli at room temperature and improve the tolerance of the lactobacilli to the metal ions in the feed; in addition, the lactobacillus microcapsule has good gastric acid resistance and can disintegrate in the intestinal canal quickly to release the lactobacilli, thereby improving the utilization rate of the lactobacilli, balancing the micro-ecological environment in the intestinal canal, suppressing the growth of pathogenic bacteria, protecting the health of the intestinal canals of animals, reducing the incidence rate of the intestinal canals of the animals and the like.

There is provided a method for controlling a flow of intestinal contents in the intestinal passageway of a patient's intestines. The method comprises gently constricting (i.e., without substantially hampering the blood circulation in the intestinal tissue wall) at least one portion of the intestinal tissue wall to influence the flow in the intestinal passageway, and stimulating the constricted wall portion to cause contraction of the wall portion to further influence the flow in the intestinal passageway. The method can be used for restricting or stopping the flow in the intestinal passageway, or for actively moving the fluid in the intestinal passageway, with a low risk of injuring the intestines.

The invention provides an Enterococcus faecium ANSE228 of which the collection number is CGMCC No.4082. The invention also provides application of the Enterococcus faecium ANSE228 to inhibition of salmonella pullorum and/or Escherichia coli and/or Staphylococcus aureus. The Enterococcus faecium ANSE228 is obtained by processes of repeated separation, purification, rejuvenation and the like, and has high biological activity, obvious probiotic property, high adversity resistance and the like. The invention also provides a microecological agent which contains the Enterococcus faecium ANSE228. When the microecological agent is added into drinking water and/or feeds for breeding animals, the Enterococcus faecium ANSE228 can be quickly activated and reproduced and a dominant beneficial flora can be formed after the Enterococcus faecium ANSE228 is fed into intestinal canals of the animals, and the Enterococcus faecium ANSE228 has the effects of reducing a harmful flora in the intestinal canals, adjusting microecological balance of the intestinal canals, substituting for medicaments such as antibiotic and the like, and improving weight increment of the animals and the utilization rate of the feeds.

The invention relates to a eubacterium and clostridium preparation and application of the same, in particular to a microecological preparation which is prepared for replenishing butyric acid bacteria and butyric acid produced by intestinal tract by taking single eubacterium, single clostridium or a eubacterium and clostridium composition as a main active composition, and application of the same in treating related diseases through butyric acid production, and belongs to the field of biological medicine.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

The present invention discloses a fruit and vegetable probiotic tablet and a preparation method thereof. The fruit and vegetable probiotic tablet uses probiotic powders such as lactobacillus plantarum powder as the main raw material, and the preparation method scientifically mixes modified dietary fibers, fruit and vegetable powder, oligosaccharides, plant extracts, protein powder, tea leaf extracts and traditional Chinese medicine extracts and etc., thus improves the content of soluble celluloses which are of real significance for probiotic flora, enhances the physiological activity of celluloses, thereby increases the species of intestinal probiotic flora as well as significantly enhances the colonization ability and time of endogenous and exogenous probiotics in the human intestinal tracts, effectively inhibits the growth and reproduction of harmful intestinal bacteria, especially gram-negative bacteria, and fully regulates the composition of the intestinal probiotic flora. The prepared fruit and vegetable probiotic tablet has a high biological activity, a long human intestinal colonization time, and a significant weight loss effect, and is suitable for a wide range of people.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

The invention provides a method for improving an intestinal colony structure and an application in the preparation of medicines, nourishment, health products, foods and beverages used for adjusting the intestinal colony. A high-flux sequence test technology and a multivariate statistical method are employed to find the intestinal colony groups which are closely related with host metabolism. According to the invention, berberine is taken as a sample to establish a novel method for improving the intestinal colony structure, the method comprises the steps of selectively increasing a part of bacteria, such as short chain aliphatic acid producing bacteria and the like, and simultaneously inhibiting a part of strain, such as bacteria capable of producing endotoxin and the like, thereby the disorders of metabolism or an immunization system due to enhancement of system inflammatory diseases induced by improper diet, obesity, insulin resistance and the like can be prevented or treated. The invention also provides a method for screening medicines, compounds and foods having the analogous effects, and a composition for improving the intestinal colony structure. The application of the method can be used for exploiting the medicines, nourishment, health products, foods, beverages and the like which take the intestinal colony as a target.

The invention relates to the technical field of microorganism, and discloses a Lactobacillus reuteri and its application. The preservation number of the Lactobacillus reuteri CCFM8631 is CGMCC No.14394; the level of mice peripheral neurotransmitter 5-hydroxytryptamine can be significantlyimproved; the rise of the mice peripheral blood testonsterone level and the abundant abnormity of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora by high glucose and high fatty diets are recovered; the tolerated simulative gastrointestinal fluid is rapidly planted in an intestinal tract, so as to significantly improve the pathological injury of metabolic syndrome mice liver and duodenum and rise of triglyceride and total cholesterol content in the serum by high glucose and high fatty diets are significantly improved; the Lactobacillus reuteri can be used for preventing, delaying or treating metabolic disorder such as metabolic syndrome, irritable bowel syndrome, and anxiety, depression and other metal diseases related to irritable bowel syndrome.

The invention discloses an enterococcus faecium EF08 as well as a feed additive and a feed containing the enterococcus faecium EF08. The enterococcus faecium EF08 is collected with the number of CGMCC (China General Microbiological Culture Collection Center) No.5549 in CGMCC. The feed additive disclosed by the invention can be used for reducing the feed excessively consumed by harmful bacteria in intestines by virtue of an equalizing effect of bacteria for equalizing the intestinal environment, furthermore, the conversion rate of the feed for economic animals is increased, the feed for the economic animals can be effectively converted into a primary animal product with an economic value, and then, the effect of increasing the economic values of the economic animals can be improved.

The invention discloses bifidobacterium longum and the application thereof and belongs to the technical field of biologics. The invention provides a bifidobacterium longum YS108R strain which has thecharacteristic of generating viscous exopolysaccharide, and has a remarkable improvement function on DSS (Dextran Sulfate Sodium) induced mouse colitis models. The strain has a relatively good capability of enduring simulated gastrointestinal fluids, is capable of remarkably reducing disease activity indexes of mice in the DSS induction period, and has an effective protection function on colon tissue. In addition, the bifidobacterium longum YS108R disclosed by the invention is separated from intestinal florae of healthy people, is free of toxic and/or side effects on human bodies, and has certain advantages when being compared with conventional medicine treatment. The strain can be used for preparing probiotic powder, fermented milk, and the like, and has wide market prospects.

The invention specifically relates to a bifidobacterium microcapsule and a preparing method thereof. The bifidobacterium is obligatorily anaerobic and very sensitive to oxygen, PH, temperature, humidity, and other adverse external environment, thereby being very hard to remain activity during production, storage and transport; besides, if taken orally in a form of dry bifidobacterium powder, the bifidobacterium cannot tolerate low-pH value gastric acid, bile salt, and other environments, so a purpose that massive survived bifidobacteria arrive at an intestinal tract and colonise on the intestinal mucosa is hard to be guaranteed. The preparing method disclosed by the invention comprises the following steps of: adding freeze-dried bifidobacterium powder into a sodium alginate solution and then mixing in soybean oil, emulsifying the mixed solution and standing; centrifugally collecting micro-capsules; and drying the micro-capsules by using a vacuum freeze-drying technology. The bifidobacterium microcapsule disclosed by the invention has the advantages of gastric acid resistance, bile salt resistance and entericsolubility, high survival rate of bifidobacterium, simple preparation method, strong practicality, convenience for industrial production, and excellent storage stability and solves the problem of short storage period of probiotics preparations.

The invention discloses a composition and an application thereof in regulating intestinal flora of animals. The composition contains aloe, probiotics and prebiotics, wherein the mass ratio of the aloe to the probiotics to the prebiotics is (6 to 3 to 1)-(6 to 1 to 3). The inventor discovers that the composition disclosed by the invention can effectively promote the proliferation of useful bacteria such as bifidobacterium and lactobacilli in animal intestines, so as to effectively regulate the intestinal flora of animals; therefore, the composition can be used for preventing or treating diabetes on the basis of the effect of the intestinal flora.

The invention relates to a degradable drug loading stent and a preparation method of the degradable drug loading stent. The degradable drug loading stent is characterized by comprising a skeleton structure made of a medical degradable metal or an alloy of the metal, a degradable macromolecular transition layer adhered to the surface of the skeleton structure and a drug loading layer. The degradable metal/macromolecular/drug multilayer composite stent provided by the invention has excellent mechanical property, degradable property and biocompatibility, and such drugs as taxol, taxol derivative, actinomycin D, 5-fluorouracil and sirolimus are loaded to the stent to perform active directional treatment on the focus position, so the stent is a functional degradable stent. The degradable multifunctional drug loading stent provided by the invention is suitable for interventional therapy in the blood vessel field and non-blood vessel fields and is especially suitable for interventional therapy of stenosis, obstruction or tumor of such non-blood vessel cavities as esophagus, bile duct, ductus pancreaticus, intestinal tract, urethral canal, trachea and bronchus, etc.

The present invention relates to a feeding acidifier prepared by emulsifying technology and a preparing method thereof. The invention belongs to the technical field of animal feed additive preparing. The feeding acidifier comprises the following components according to content: 8-20 parts of lemon acid; 5-20 parts of fumaric acid; 10-15 parts of phosphoric acid; 5-20 parts of malic acid; 15-25 parts of lactic acid; 6-15 parts of formic acid; 2-10 parts of acetic acid; 2-5 parts of mouthfeel modifying agent; and 3-5 parts of silicon dioxide. The invention provides a novel preparation form of acidifier and combines the physical and chemical properties of shaping material for developing the novel producing technique of acidifier according to the sustained-release control principle. The feeding acidifier prepared according to the emulsifying technique of the invention effectively settles the problem of stomach digesting of acidifier and the effect directly gets to the intestinal canal. The feeding acidifier prepared by emulsifying technology according to the invention has the advantages of reliable safety, excellent free-running property, strong moisture absorption resistance, convenient processing, growth promotion, diarrhea prevention, etc.

Using RNA samples from mononuclear blood cells, gene sequences were identified that can be used to identify patients with IBD, and then distinguish patients with Crohn's disease from those with ulcerative colitis. Sequences were identified whose overexpression was distinct to patients with IBD, Crohn's disease, and ulcerative colitis when compared to patients with non-IBD intestinal disorders. Additionally, cluster analysis was used to identify twenty-five sequences that are IBD-related, and whose transcription pattern can be used in a microarray analysis to identify patients with IBD with a sensitivity of 84% and a specificity of 100%. Cluster analysis also identified thirty-six genes that could be used to distinguish patients with Crohn's disease from those with ulcerative colitis with a sensitivity of 89% and a specificity of 80%.

The invention provides a Bacillus coagulans HEW-B379 with a probiotic effect. The above strain is named as HEW-B379, and the preservation number of the strain is CGMCC No.12553. The Bacillus coagulans HEW-B379 has a substantial probiotic property, and can effectively inhibit growth breeding of enteropathogenic Escherichia coli, Staphylococcus aureus, Salmonella typhi, salmonella, Shigella, Proteus species, Shewanella putrefaciens and Pseudomonas aeruginosa. The Bacillus coagulans HEW-B379 has strong stress resistance, can resist high temperature and simulated gastric juice and simulate bile salt environment, can keep the survival rate of 99-100%, and can effectively adjust microbial balance of animal intestinal tracts, inhibit growth of harmful microbes, promote nutrition absorption of animals, improve the conversion rate of a feed and improve the productivity of the animals.